Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

Leyten, G.H.J.M.; Hessels, Daphne; Smit, Frank; Jannink, Sander A.; Jong, Hans de; Melchers, Willem J. G.; Cornel, Erik B.; Reijke, Theo M. de; Vergunst, H.; Kil, Paul; Knipscheer, Ben C.; Kaa, Christina A. Hulsbergen‐van de; Mulders, Peter F.A.; Oort, Inge M. van; Schalken, Jack A.

doi:10.1158/1078-0432.ccr-14-3334

Cited by 203 publications

(172 citation statements)

References 33 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Indeed, targeted cancer panels are currently most commonly used as diagnostic and prognostic tools in clinical oncology due to their advantages such as low cost and relatively simple interpretation [45,46]. Breast cancer (BC) is a good example of the application of NGS as an effective method to increase the detection rate of high-risk cases [47]. Previous studies have shown that BRCA1 and BRCA2 mutations cause about 30% of BC cases.…”

Section: Advantages Of Ngs Technologiesmentioning

confidence: 99%

The applications of massive parallel sequencing (next-generation sequencing) in research and molecular diagnosis of human genetic diseases

Nguyen¹,

Le²,

Nguyen³

et al. 2018

VJSTE

View full text Add to dashboard Cite

Abstract:Next-generation sequencing (NGS) is a high throughput sequencing technology, which has revolutionized both basic and clinical research of the human genetic disorders. This technology is also called massively parallel sequencing (MPS) due to its ability to generate a huge amount of output data in a cost-and time-effective manner. NGS is widely utilized for different sequencing applications such as targeted sequencing (a group of candidate genes), exome sequencing (all coding regions), and whole genome sequencing (the entire human genome). With NGS, a variety of genomic aberrations can be screened simultaneously such as common and rare variants, structural variations (amplifications and deletion), copy-number variation, and fusion transcripts. NGS technologies combined with advanced bioinformatic analysis have tremendously expanded our knowledge. On the one hand, the basic research area involves direct use of NGS to identify novel variations and determine human disease mechanisms. On the other hand, clinical research is being advanced by highthroughput genetic tests with high resolution and clinically relevant genetic information for molecular diagnoses of human disorders. In this communication, we introduce NGS technologies and review a few key areas where NGS has made a significant impact, with an emphasis on the application of NGS to the identification of the molecular bases of human genetic diseases.

show abstract

Section: Advantages Of Ngs Technologiesmentioning

confidence: 99%

The applications of massive parallel sequencing (next-generation sequencing) in research and molecular diagnosis of human genetic diseases

Nguyen¹,

Le²,

Nguyen³

et al. 2018

VJSTE

View full text Add to dashboard Cite

show abstract

“…The HOXC6 and DLX1 homeobox genes are upregulated in prostate cancer cells and their expression increases during the progression of cancer to a higher-grade, castration-resistant and metastatic stage (55,56). The Mi-Prostate Score combined the expression signatures of urine ERG-TMPRSS2 and PCA3 with serum PSA, may improve the prediction of cancer risk and high-grade cancer following biopsy (57).…”

Section: Non-invasive Genetic Biomarker Testmentioning

confidence: 99%

The context of prostate cancer genomics in personalized medicine

Liu

2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Prostate cancer is one of the most common types of cancer in males. Heterogeneous genomic aberrations may lead to prostate cancer onset, progression and metastasis. This heterogeneity also contributes to the variety in cancer risk and outcomes, different drug responses and progression, observed between individual patients. Classical prognostic factors, including prostate-specific antigen, Gleason Score and clinical tumor staging, are not sufficient to portray the complexity of a clinically relevant cancer diagnosis, risk prognosis, treatment choice and therapy monitoring. There is a requirement for novel genetic biomarkers in order to understand the oncogenic heterogeneity in a patient-personalized clinical setting and to improve the efficacy of risk prognosis and treatment choice. A number of biomarkers and gene panels have been established from patient sample cohort studies. These previous studies have provided distinct information to the investigation of heterogeneous malignancy in prostate cancer, which aids in clinical decision-making. Biomarker-guided therapies may facilitate the effective selection of drugs during early treatment; therefore, are beneficial to the individual patient. A non-invasive approach allows for convenient and repeated sampling to screen for cancer and monitor treatment response without the requirement for invasive tissue biopsies. With the current availability of numerous advanced technologies, reliable detection of the minimal tumor residues present following treatment may become clinical practice and, therefore, inform further in the field of personalized medicine.

show abstract

“…Одна из них включала гены РСА3, ELF3, SPP1 и HIST1H2BG, другая -PCA3 и TMPRSS2: ERG с ис-пользованием Progensa и новой тест-системы Т2ERG (Hologic), еще в одной работе анализировали экспрес-сию 12 генов [26][27][28]. Опубликованы панели экспрес-сионных маркеров без РСА3, также направленные на диагностику РПЖ по осадку мочи, которые вклю-чают гены DLX1 и HOXC6 [29][30][31].…”

Section: сравнительный анализ экспрессии гена рса3: а -Roc-анализ эксunclassified

Comparative analysis of the PCA3 gene expression in sediments and exosomes isolated from urine

Михайленко¹,

Новиков²,

Григорьева³

et al. 2017

Cancer Urology

View full text Add to dashboard Cite

Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

Cited by 203 publications

References 33 publications

The applications of massive parallel sequencing (next-generation sequencing) in research and molecular diagnosis of human genetic diseases

The applications of massive parallel sequencing (next-generation sequencing) in research and molecular diagnosis of human genetic diseases

The context of prostate cancer genomics in personalized medicine

Comparative analysis of the PCA3 gene expression in sediments and exosomes isolated from urine

Contact Info

Product

Resources

About